Nautilus Biotechnology, Inc. (NAUT) Income Statement
NAUT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNAUT revenue and net income
NAUT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NAUT quarterly EPS vs estimates
Nautilus Biotechnology beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 27, 2026 (estimate $-0.14).
NAUT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $6.5M | $6.4M | $5.7M | $3.4M | $2.8M | $2.3M | — | — |
| Gross profit | −$6.5M | −$6.4M | −$5.7M | −$3.4M | −$2.8M | −$2.3M | — | — |
| Research & development | $41.1M | $50.5M | $47.3M | $37.7M | $26.5M | $10.1M | $8.5M | — |
| Sales, general & admin | $25.7M | $31.0M | $28.9M | $25.9M | $21.1M | $3.3M | $1.6M | $111.7M |
| Total operating expenses | $60.4M | $75.1M | $70.4M | $63.6M | $47.7M | $13.4M | $10.1M | $111.7M |
| Operating income | −$66.8M | −$81.5M | −$76.2M | −$63.6M | −$50.5M | −$15.7M | −$10.1M | −$111.7M |
| Interest income | $7.9M | $10.8M | $12.4M | $5.8M | $329,000 | $52,950 | — | — |
| Interest expense | — | — | — | $5.8M | $183,000 | $0 | $0 | $0 |
| Income before taxes | −$59.0M | −$70.8M | −$63.7M | −$57.9M | −$50.3M | −$15.6M | −$9.6M | $626.6M |
| Income taxes | — | −$70.8M | — | $5.8M | $2.6M | $2.1M | −$171,312 | $738.1M |
| Net income | −$59.0M | −$70.8M | −$63.7M | −$57.9M | −$50.3M | −$15.6M | −$9.6M | $626.6M |
| EBITDA | −$52.5M | −$64.4M | −$58.0M | −$60.1M | −$47.5M | −$13.3M | −$9.6M | $626.6M |
| EPS (diluted) | −$0.47 | −$0.56 | −$0.52 | −$0.47 | −$0.79 | −$0.03 | −$1.34 | $87.17 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190,000 | $0 | $0 | $0 | $0 | $0 | $9.6M | $0 | $0 | $0 | $8.2M | $0 |
| Cost of revenue | −$1.1M | $1.5M | $1.6M | $1.6M | $1.6M | $1.6M | $6.4M | $1.6M | $1.6M | $1.6M | $1.6M | $1.5M |
| Gross profit | $1.3M | −$1.5M | −$1.6M | −$1.6M | −$1.6M | −$1.6M | −$6.4M | −$1.6M | −$1.6M | −$1.6M | −$1.6M | −$1.5M |
| Research & development | $9.6M | $9.4M | $10.9M | $9.6M | $10.4M | $11.5M | $10.8M | $11.8M | $11.9M | $12.4M | $11.9M | $11.5M |
| Sales, general & admin | $6.3M | $6.4M | $5.8M | $5.9M | $6.7M | $7.3M | $7.2M | $6.8M | $8.4M | $8.7M | $7.5M | $7.1M |
| Total operating expenses | $17.1M | $14.6M | $13.8M | $15.5M | $17.1M | $18.8M | $13.6M | $17.5M | $19.2M | $20.0M | $18.4M | $17.6M |
| Operating income | −$15.8M | −$16.1M | −$15.4M | −$15.5M | −$17.1M | −$18.8M | −$20.0M | −$19.1M | −$20.8M | −$21.6M | −$20.0M | −$19.1M |
| Interest income | $1.3M | $1.4M | $1.7M | $1.9M | $2.1M | $2.2M | $2.4M | $2.7M | $2.8M | $2.9M | $3.0M | $3.2M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $3.1M | — |
| Income before taxes | −$14.5M | −$14.7M | −$13.8M | −$13.6M | −$15.0M | −$16.6M | −$17.6M | −$16.4M | −$18.0M | −$18.7M | −$17.0M | −$15.9M |
| Income taxes | — | — | — | — | — | — | — | $1.0M | — | $1.5M | −$3.0M | $3.2M |
| Net income | −$14.5M | −$14.7M | −$13.8M | −$13.6M | −$15.0M | −$16.6M | −$17.6M | −$16.4M | −$18.0M | −$18.7M | −$17.0M | −$15.9M |
| EBITDA | −$14.5M | −$13.2M | −$12.2M | −$13.8M | −$15.4M | −$17.2M | −$11.2M | −$14.8M | −$16.4M | −$17.1M | −$15.4M | −$14.4M |
| EPS (diluted) | −$0.11 | −$0.12 | −$0.11 | −$0.11 | −$0.12 | −$0.13 | −$0.14 | −$0.13 | −$0.14 | −$0.15 | −$0.14 | −$0.13 |
| Gross margin | 693.2% | — | — | — | — | — | −66.2% | — | — | — | −19.4% | — |
| Operating margin | −8,296.3% | — | — | — | — | — | −208.1% | — | — | — | −243.6% | — |
| Net margin | −7,615.3% | — | — | — | — | — | −183.3% | — | — | — | −207.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NAUT's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NAUT financial results
Nautilus Biotechnology reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $59.0 million. Diluted earnings per share came to −$0.47.
See the NAUT stock overview for the latest quote and news, or the NAUT chart for price history and technical indicators.
NAUT income statement FAQ
Does Nautilus Biotechnology have revenue?
Nautilus Biotechnology reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Nautilus Biotechnology profitable?
No. Nautilus Biotechnology reported a net loss of $59.0 million in fiscal 2025.
How much does Nautilus Biotechnology spend on research and development?
Nautilus Biotechnology spent $41.1 million on research and development in fiscal 2025.
What are Nautilus Biotechnology's earnings per share?
Nautilus Biotechnology earned $-0.47 per diluted share in fiscal 2025, compared with $-0.56 a year earlier.
When will Nautilus Biotechnology report its next earnings?
Nautilus Biotechnology is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 before the market opens.
When does Nautilus Biotechnology's fiscal year end?
Nautilus Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.